Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives

Yung Yeh Su, Chia Chen Li, Yih Jyh Lin, Chiun Hsu

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)

Abstract

Advancement in systemic therapy, particularly immune checkpoint inhibitor (ICI)-based combination regimens, has transformed the treatment landscape for patients with advanced hepatocellular carcinoma (HCC). The advancement in systemic therapy also provides new opportunities of reducing recurrence after curative therapy through adjuvant therapy or improving resectability through neoadjuvant therapy. Improved recurrence-free survival by adjuvant or neoadjuvant ICI-based therapy has been reported in other cancer types. In this article, developments of systemic therapy in adjuvant and neoadjuvant settings for HCC were reviewed. The design of adjuvant and neoadjuvant therapy using ICI-based regimens and potential challenges of trial conduct and result analysis was discussed. Results from these trials may extend the therapeutic benefit of ICI-based systemic therapy beyond the advanced-stage disease and lead to a new era of multidisciplinary management for HCC.

Original languageEnglish
Pages (from-to)263-276
Number of pages14
JournalSeminars in Liver Disease
Volume41
Issue number3
DOIs
Publication statusPublished - 2021 Aug 1

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint

Dive into the research topics of 'Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives'. Together they form a unique fingerprint.

Cite this